LOGIN
ID
PW
MemberShip
2024-12-13 02:09
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
InterView
¡®3 IBD treatment trends¡¦early treatment is the first¡¯
by
Kim, Jin-Gu
Dec 2, 2024 05:49am
The treatment method for a single disease can continue to change at a very fast pace. This is true for inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease. In recent years, a variety of drugs have been developed to treat these diseases, and the treatment trend is changing as more research is conducted. Dr. Ju
InterView
¡®Improve new drug access to treat rheumatoid arthritis'
by
Son, Hyung Min
Nov 21, 2024 05:46am
¡°Rheumatoid arthritis is not just a painful disease, but a disease that can cause direct damage to the joints. Patients need to start treatment with good treatments in a timely manner, but their access to new drugs is still limited. Switching between JAK inhibitors should be allowed freely so patients can receive personalized treatment.¡±
InterView
'Early detection of RA can help prevent severe symptoms'
by
Whang, byung-woo
Nov 14, 2024 05:51am
"Rheumatoid arthritis not only induces permanent joint deformities and damages but also has a detrimental effect on quality of life due to many general symptoms. As effective disease management becomes possible following the recent introduction of various treatment options, early diagnosis and patient-customized treatment approach are crucial."
InterView
"Recruiting a company to co-develop pitavastatin+ezetimibe"
by
Kim, Jin-Gu
Oct 30, 2024 05:54am
Shinil Pharmaceutical will collaborate with other biopharmaceutical company to co-develop a generic 'pitavastatin+ezetimibe' combination drug for treating hyperlipidemia. Through joint-collaboration, Shinil Pharmaceutical plans to improve not only the contract manufacturing of medicines but also cost savings and productivity. In the mean
InterView
"JAK inhibitors bring a paradigm shift to RA treatment"
by
Whang, byung-woo
Oct 16, 2024 05:50am
As patients with autoimmune diseases, including rheumatoid arthritis, have better access to medical care, early diagnosis and treatment have been pointed out as the key. Early diagnosis and treatments previously available in university hospitals are now possible in local clinics. As a result, patient-personalized therapies, even for patients
InterView
"An OTC drug increases lymphedema patient satisfaction"
by
Kim, Jin-Gu
Sep 23, 2024 05:50am
Lymphedema occurs when the body's flow of lymph fluid is disrupted. Due to a particular reason, the build-up of lymph fluid between cells causes swelling and hardening of fatty tissues in the arms and legs. Unfortunately, the number of medicines for treating lymphedema is limited. Therefore, there are unmet needs in clinical practices. Hence
InterView
¡®Era of once-weekly growth hormones¡¦adherence is key¡¯
by
Hwang, Byung-woo
Sep 13, 2024 05:49am
"The frequency of drug administration is an important factor in the treatment of growth hormone deficiency. The emergence of a once-weekly dosing option is significant in terms of treatment adherence.¡¯ With the market for growth hormone injections rising rapidly, the diversified treatment options have been increasing market interest. The
InterView
"New targeted therapies for bile duct cancer are in need"
by
Son, Hyung-Min
Sep 6, 2024 05:48am
"Recently, as many companies have conducted various studies in the field of cholangiocarcinoma, effective drugs like Tibsovo have become available in the market. Although the development of targeted therapy for cholangiocarcinoma was highly possible, like lung cancer, studies and investments have been insufficient until now. We are seeing po
InterView
AstraZeneca seeks mutual growth through open collaboration
by
Hwang, Byung-woo
Aug 27, 2024 05:50am
Multinational pharmaceutical companies are increasingly investing in R&D in Korea¡¯s domestic pharmaceutical industry through open innovation. According to the Korean Research-based Pharmaceutical Industry Association (KRPIA), the total amount of R&D invested in clinical research in Korea in 2022 was KRW 817.8 billion and has been on t
InterView
¡®We need to actively use acetaminophen ER tablets'
by
Eo, Yun-Ho
Jul 18, 2024 05:49am
The use of extended-release formulations is increasing in the field of analgesics. Acetaminophen-based medicines, which consumers commonly regard as cold and fever relievers, are usually given in the form of IR tablets (Immediate Release tablets), which are regular tablets that dissolve quickly in the stomach without any special controlle
1
2
3
4
5
6
7
8
9
10
>